Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Long-term safety and tolerability as measured by treatment-emergent adverse events (AEs) and treatment-emergent serious adverse events (SAEs) up to 30 days following discontinuation of the study drug. [ Time Frame: 40 weeks post completion of the APD334-003 study ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who completed the APD334-003 study
Patients who did not complete the APD334-003 study